PDCD1 and melanoma: observed reductions in the TMB and neoantigen load, along with notable gene expression changes and shifts in the T cell receptor (TCR) repertoire in melanoma patients responsive to anti‐PD‐1 therapy.[60] In contrast, Anagnostou et al.